Use of Jun inhibitors in the preparation of a medicament for treating heart failure with preserved ejection fraction
Jun inhibitors address the lack of effective treatments for HFpEF by suppressing Jun expression, thereby improving diastolic function and reducing disease progression.
JP2025524214AActive Publication Date: 2025-07-25ベイジン·バヒール·ウィサート·メディカル·リサーチ·カンパニー·リミテッド
Patent Information
- Application Number
- JP2025504842
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-30
- Filing Date
- 2023-07-28
- Publication Date
- 2025-07-25
- Estimated Expiration
- 2043-07-28
AI Technical Summary
Technical Problem
Current treatments for heart failure with preserved ejection fraction (HFpEF) are limited, and there is an urgent need for effective agents to manage this condition, which is associated with high morbidity and mortality.
Method used
The use of Jun inhibitors, such as T-5224, to suppress the high expression of the Jun gene and its signaling, which are administered to treat or prevent HFpEF.
Benefits of technology
Jun inhibitors effectively alleviate the progression of HFpEF by improving diastolic function and reducing Jun expression, demonstrating a preventive and therapeutic effect in animal models.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2025524214000001_ABST
Abstract
The present invention relates to the use of Jun inhibitors in the manufacture of a medicament for treating heart failure with preserved ejection fraction (HFpEF).
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Apoptosis signal-regulating kinase inhibtor
WO2018169742A1